Addex Full Year 2008 Financial Results Next Tuesday

Conference call & webcast at 15:00 CET on 24 February 2009
Geneva, Switzerland, 17 February 2009- Allosteric modulation company
Addex Pharmaceuticals (SIX:ADXN) will discuss its 2008 full year
financial results during a conference call and webcast for investors,
analysts and the media on Tuesday, 24 February 2009 at 15:00 CET.
Also on the 24th, the financial results press release will be issued
prior to the start of trading on the SIX Swiss Exchange stock market.

Addex Full Year 2008 Financial Results Conference Call:

Date: 24 February 2009
Time: 15:00 CET
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)

A live webcast, slides, webcast replay and transcript will be made
available at www.addexpharma.com

Addex Pharmaceuticals (www.addexpharma.com) discovers and develops
allosteric modulators for human health. Allosteric modulators are a
different kind of orally available small molecule therapeutic agent,
which we believe will offer patients better results than classical
drugs. Our lead allosteric modulator product, ADX10059, has achieved
clinical proof of concept and is in Phase IIb testing for the
treatment of GERD and, separately, migraine headache. Both are
important diseases for which existing products have established
multi-billion dollar markets despite sub-optimal efficacy. ADX10059
is a first-in-class mGluR5 inhibitor, a therapeutic strategy that
also is being pursued to treat multiple indications by large pharma
competitors.
Our product pipeline and technology already have proven their value
through our relationships with four of the top 10 pharmaceutical
companies in the world. Specifically, in two separate license
agreements with Merck & Co., Inc., we are developing positive
allosteric modulators of mGluR4 and mGluR5 as drugs to treat
Parkinson's disease and schizophrenia, respectively. A third
agreement, with Ortho McNeil Pharmaceuticals inc., a Johnson &
Johnson company, is focused on development of positive allosteric
modulators of mGluR2 to treat anxiety and schizophrenia. Separately,
investment funds from Roche and GlaxoSmithKline have extended their
validation of our technology, products and management by making
significant investments in Addex.

Chris Maggos
Head of Investor Relations & Communications
Addex
Pharmaceuticals
+41 22 884 15 11 Direct
chris.maggos@addexpharma.com

Disclaimer: The foregoing release contains forward-looking statements
that can be identified by terminology such as "not approvable",
"continue", "believes", "believe", "will", "remained open to
exploring", "would", "could", or similar expressions, or by express
or implied discussions regarding Addex Pharmaceuticals Ltd, its
business, the potential approval of its products by regulatory
authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views
of Addex Pharmaceuticals Ltd regarding future events, and involve
known and unknown risks, uncertainties and other factors that may
cause actual results with allosteric modulators of mGluR4, mGluR2 or
mGluR5 to be materially different from any future results,
performance or achievements expressed or implied by such statements.
There can be no guarantee that allosteric modulators of mGluR4,
mGluR2 or mGluR5 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric
modulators of mGluR4, mGluR2 or mGluR5 will achieve any particular
levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR4, mGluR2 or
mGluR5 could be affected by, among other things, unexpected actions
by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results,
including unexpected new clinical data and unexpected additional
analysis of existing clinical data; competition in general;
government, industry and general public pricing pressures; the
company's ability to obtain or maintain patent or other proprietary
intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated,
believed, estimated or expected. Addex Pharmaceuticals is providing
the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.